Objective To evaluate the clinical curative effect of intravitreal injection of ranibizumab combined with retrobulbar injection of methylprednisolone for the treatment of macular edema secondary to retinal vein occlusion(CRVO). Methods The patients underwent routine intravitreal ranibizumab injection needle who were diagnosed as macular edema secondary to non ischemic retinal vein occlusion with the examination of FFA and OCT, There were 37 cases of recurrence of macular edema after the 3 needle(37 eyes),and they were randomly divided into observation group(19 eyes of 19 cases)and control group(18 eyes of 18 cases). The control group according to the need of intravitreal ranibizumab injection needle,the observation group according to the need of retrobulbar injection of methylprednisolone needle. Results The observation group and the control group before and after surgery were compared at 1 months,3 months 6 months after surgery,the best corrected visual acuity,foveal thickness showed no significant difference(P>0.05)1 weeks after surgery,the best corrected visual acuity,foveal thickness difference had statistics significance(P<0.05). There was no significant difference between the observation group and the control group before and after 1 weeks of operation, after the operation for 1 months,at the time of 3 months,and after the operation for 6 months(P>0.05). Comparison of foveal thickness for 6 months in the observation group and the control group before and after surgery for 1 months,3 months after surgery,after surgery,there were no significant differences(P>0.05),compared the foveal thickness 1 weeks after surgery,the difference was statistically significant(P<0.05). Conclusion Intravitreal injection of ranibizumab combined with retrobulbar injection of methylprednisolone injection can effectively relieve macular edema secondary to retinal vein occlusion,and improve visual acuity in patients after treatment.%目的 评价玻璃体腔注射雷珠单抗联合球后注射甲泼尼龙针治疗视网膜静脉阻塞(CRVO)继发黄斑水肿的临床疗效.方法 经荧光血管造影(FFA)及光学相干断层扫描(OCT)检查确诊为非缺血型视网膜静脉阻塞继发黄斑水肿的患者,已行常规玻璃体腔注射雷珠单抗针3针后再次复发黄斑水肿的患者37例(37眼),随机分成观察组(19例19眼)和对照组(18例18眼).对照组根据需要再次玻璃体腔注射雷珠单抗针,观察组根据需要球后注射甲泼尼龙针.结果 观察组和对照组术前、术后1个月、术后3个月、术后6个月的最佳矫正视力、黄斑中心凹厚度比较差异均无统计学意义(P>0.05),术后1周的最佳矫正视力、黄斑中心凹厚度比较差异具有统计学意义(P<0.05).观察组和对照组术前、术后1周、术后1个月、术后3个月、术后6个月眼压比较,差异均无统计学意义(P>0.05).观察组和对照组术前、术后1个月、术后3个月、术后6个月的黄斑中心凹厚度比较,差异均无统计学意义(P>0.05),术后1周的黄斑中心凹厚度比较,差异具有统计学意义(P<0.05).结论 玻璃体腔注射雷珠单抗联合球后注射甲泼尼龙针方法可有效减轻视网膜静脉阻塞继发的黄斑水肿,并提升治疗后患者视力.
展开▼
